{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.33"}]}],"title":"10^-5 threshold MRD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.33"}]}],"title":"10^-6 threshold MRD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"MRD negativity rate: percentage of participants with negative MRD (assessed by central laboratory) per IMWG criteria at any time from date of first dose until first documentation of confirmed progression, death or start of new anticancer therapy, whichever occurred first. Progression was defined as appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types. MRD negativity was defined by two thresholds, 10\\^-5 and 10\\^-6.","groups":[{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 44 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 76 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 2A: PF-06863135 SC"}],"paramType":"NUMBER","populationDescription":"Safety Analysis set included all participants who received at least 1 full or partial dose of study medication.","reportingStatus":"POSTED","timeFrame":"Anytime from date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy whichever occurred first (maximum up to 34.3 months)","title":"Part 2: Percentage of Participants With Negative MRD After Treatment With PF-06863135 Using IMWG MRD Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}